February 11, 2025 09:25 AM ESTUpdated 12:05 PM
People
R&D

In­ven­ti­va cuts pipeline, lays off near­ly en­tire re­search team in bid to get to Phase 3 MASH read­out

Max Gelman

Senior Editor

In­ven­ti­va is trim­ming its pipeline and en­act­ing lay­offs in an ef­fort to get its lead MASH drug ap­proved, the com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Up­dat­ed: Judge halts NIH cuts na­tion­wide af­ter groups, 22 states sue

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times